Quote | Candel Therapeutics Inc. (NASDAQ:CADL)
Last: | $12.70 |
---|---|
Change Percent: | -0.71% |
Open: | $14.1 |
Close: | $12.70 |
High: | $14.3 |
Low: | $12.4233 |
Volume: | 1,017,190 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Candel Therapeutics Inc. (NASDAQ:CADL)
2024-05-16 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-14 14:35:37 ET More on Candel Therapeutics Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment Candel stock soars on positive data from m...
Message Board Posts | Candel Therapeutics Inc. (NASDAQ:CADL)
Subject | By | Source | When |
---|---|---|---|
$CADL here we go bulls news is here | MiamiGent | investorshub | 04/25/2023 7:34:02 PM |
where is the squeeze? | subslover | investorshub | 04/25/2023 7:07:26 AM |
$CADL got some short data | MiamiGent | investorshub | 04/23/2023 9:01:49 AM |
where is the squeeze? | subslover | investorshub | 04/17/2023 10:33:11 AM |
$CADL Looks pretty positive | axelvento | investorshub | 04/04/2023 11:28:03 AM |
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
2024-05-16 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wedn...
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024 On track for top...